A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy

John A. Glaspy(University of California, Los Angeles), Alan Colowick(Amgen (United States)), James R. Rigas(Dartmouth–Hitchcock Medical Center), J. Jadeja(Hematology Oncology Associates), David J. Kuter(Harvard University), George D. Demetri(American Society of Clinical Oncology), Debra M. Prow(Cancer Care Services), J O’Byrne(Amgen (United States)), Derek Richards, Lee S. Schwartzberg(Renown Health), Alan Saven(Scripps Research Institute), David Gordon(Massachusetts General Hospital), James C. Arseneau(Regional Cancer Center), J. Keßler(Virginia Oncology Associates), Harry E. Hynes, Glen R. Justice(Orange Coast Memorial Medical Center), Ralph V. Boccia(Center for Cancer and Blood Disorders), David C. Harmon(Massachusetts General Hospital)
British Journal of Cancer
January 1, 2001
Cited by 81


Related Papers